Regulatory China’s NMPA approves Akeso’s gumokimab for plaque psoriasis Pharmaceutical Business ReviewThe approval is based on data from one pivotal Phase III trial (AK111-301) and three additional supportive studies.Immunology & InflammationRead full story pharminent June 12, 2026 (Last updated: June 19, 2026) Pharmaceutical Business Review The approval is based on data from one pivotal Phase III trial (AK111-301) and three additional supportive studies. Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: How Medicare Advantage Rebates Disadvantage Medicare’s Stand-Alone Drug Plan MarketNext: Novo Nordisk comeback stirs as Wegovy pill wins UK approval Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
